Santen Pharmaceutical

Eyevance Pharmaceuticals LLC, established in 2017 and headquartered in Fort Worth, Texas, is a subsidiary of Santen Holdings U.S. Inc., dedicated to developing and commercializing innovative ophthalmic products. The company's portfolio includes TOBRADEX ST for treating inflammatory ocular conditions, ZERVIATE for alleviating severe eye itch, FLAREX for managing anterior segment inflammation, NATACYN for treating fungal infections, and FRESHKOTE for addressing dry eye symptoms. Eyevance focuses on addressing unmet medical needs in ophthalmology to improve patients' vision and quality of life.

Plano is a company focused on addressing the growing global crisis of myopia, or short-sightedness, which currently affects 1.5 billion individuals and is projected to rise to 5 billion by 2050. Recognizing the link between increased screen time and the prevalence of myopia, Plano has developed a science-based parental control application aimed at promoting eye health and ensuring children's safety in the digital environment. The application offers various features, including eye health check software, myopia screen management tools, and engaging events and games designed to educate users about eye health. By combining technology and health awareness, Plano aims to empower families to combat the myopia epidemic and enhance overall quality of life for children.

QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrates for various applications in communications and industry. Established in 2006 and based in Kawasaki, Japan, the company specializes in creating a diverse range of high-performance laser products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, QD Laser produces broadband gain chips for ophthalmic testing and retinal imaging laser eyewear. Their technology serves multiple sectors, including telecommunications, manufacturing, medicine, and consumer products, allowing for advancements in fields like silicon photonics, sensing, and precision machining.

QD Laser, Inc. is a manufacturer of quantum dot semiconductor lasers and wafers, utilizing GaAs substrates for various applications in communications and industry. Established in 2006 and based in Kawasaki, Japan, the company specializes in creating a diverse range of high-performance laser products, including picosecond short-pulse DFB lasers for precision processing, current injection-type lasers in green, yellow-green, and orange for biological sciences, and quantum dot laser arrays for silicon optical circuits. Additionally, QD Laser produces broadband gain chips for ophthalmic testing and retinal imaging laser eyewear. Their technology serves multiple sectors, including telecommunications, manufacturing, medicine, and consumer products, allowing for advancements in fields like silicon photonics, sensing, and precision machining.

International Biomedical Devices (IBMD) is an early-stage medical device company focused on ophthalmology innovations. At present, the company is leading the emerging, non-laser based, precision capsulotomy category through the development of a unique and much-needed new capsulotomy technology. It was founded in 2013 and is based in Charleston, South Carolina.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

InnFocus is a biomaterials company, develops and provides products in ophthalmology. The company's product portfolio includes an intraocular lens for microincision surgery and an implantable device for glaucoma. The company was incorporated in 2003 and is based in Miami, Florida.

RetroSense Therapeutics is a biotechnology company developing life-enhancing gene therapies designed to restore vision in patients suffering from blindness due to retinitis pigmentosa (RP) and advanced dry age-related macular degeneration (advanced dry-AMD). There are currently no FDA approved drugs to improve or restore vision in patients with these retinal degenerative conditions. The company's approach to using optogenetics in vision restoration is based on pioneering, proprietary research conducted at Wayne State University and Massachusetts General Hospital. Founded in 2009, RetroSense Therapeutics is headquartered in Ann Arbor, Michigan.

TearSolutions, Inc. is a biotechnology company based in Charlottesville, Virginia, founded in 2013. The company focuses on developing innovative therapies for dry eye conditions, particularly through its proprietary product, Lacripep. This synthetic peptide treatment is designed to mimic the natural tear protein lacritin, aiming to restore basal tearing and improve corneal health without causing irritation. TearSolutions is currently advancing Lacripep through phase II human clinical trials, targeting patients with primary Sjögren's syndrome. The company's approach preserves the biological activity of natural tear proteins while providing a scalable solution to address the symptoms of dry eyes effectively.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.